Lineage Cell Therapeutics, Inc. - FORM 10-K - EX-32 - EXHIBIT 32.1 - March 11, 2015

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Lineage Cell Therapeutics, Inc.Financial_Report.xls
EX-31 - EXHIBIT 31 - Lineage Cell Therapeutics, Inc.ex31.htm
EX-23.1 - EXHIBIT 23.1 - Lineage Cell Therapeutics, Inc.ex23_1.htm
EX-21.1 - EXHIBIT 21.1 - Lineage Cell Therapeutics, Inc.ex21_1.htm
EX-23.2 - EXHIBIT 23.2 - Lineage Cell Therapeutics, Inc.ex23_2.htm
EX-10.65 - EXHIBIT 10.65 - Lineage Cell Therapeutics, Inc.ex10_65.htm
EX-10.62 - EXHIBIT 10.62 - Lineage Cell Therapeutics, Inc.ex10_62.htm
EX-10.61 - EXHIBIT 10.61 - Lineage Cell Therapeutics, Inc.ex10_61.htm
EX-10.64 - EXHIBIT 10.64 - Lineage Cell Therapeutics, Inc.ex10_64.htm
EX-10.63 - EXHIBIT 10.63 - Lineage Cell Therapeutics, Inc.ex10_63.htm
10-K - BIOTIME, INC 10-K 12-31-2014 - Lineage Cell Therapeutics, Inc.form10k.htm
Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of BioTime, Inc. (the “Company”) for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Michael D. West, Chief Executive Officer, and Robert W. Peabody, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 10, 2015

 
/s/Michael D. West
  
 
Michael D. West
  
 
Chief Executive Officer
  
     
 
/s/Robert W. Peabody
  
 
Robert W. Peabody
  
 
Chief Financial Officer
  
 
 

Lineage Cell Therapeutics, Inc. Reports